Pathogenetic and clinical implications of Bcl-6 and Bcl-2 gene configuration in nodal diffuse large B-cell lymphomas

The Journal of Pathology
E PescarmonaF Le Coco

Abstract

Bcl-6 (LAZ-3) and Bcl-2 gene rearrangements have been respectively reported in 20-35 per cent and 10-25 per cent of diffuse large B-cell lymphomas (DLBCLs). Although these genetic lesions have been associated with different clinical outcomes (i.e., more favourable in Bcl-6 rearranged cases and poorer in Bcl-2 rearranged cases), their prognostic significance is still controversial. In the present study, we have investigated by Southern blot analysis the Bcl-6 and Bcl-2 gene configuration in a series of 80 lymph nodes involved by well-characterized DLBCLs, histologically defined according to the REAL and the updated Kiel classifications. The molecular findings have been correlated with the clinical features at presentation and with response to therapy. The majority of cases (57/80 = 71.2 per cent) had a centroblastic morphology. Bcl-6 rearrangements were detected in 23/80 cases (28.8 per cent), and were similarly associated with centroblastic (18/57 = 31.6 per cent) or immunoblastic (3/11 = 27.3 per cent) histotypes. In contrast, Bcl-2 was found to be rearranged in only three cases of centroblastic lymphoma (3.8 per cent). No significant differences were found between Bcl-6 rearranged and germline cases, as far as the clinical fe...Continue Reading

References

Apr 1, 1992·The American Journal of Surgical Pathology·W R MaconJ B Cousar
Nov 1, 1991·Mechanisms of Development·T el-Baradi, T Pieler
Nov 23, 1989·Nature·J Mallet
Feb 6, 1988·Lancet·A G StansfeldO Mioduszewska
Jun 1, 1988·The American Journal of Surgical Pathology·A D RamsayP G Isaacson
Nov 5, 1987·The New England Journal of Medicine·L M WeissM L Cleary
Jul 14, 1994·The New England Journal of Medicine·K OffitA Rosenbaum
Nov 1, 1995·Histopathology·H TobiokaM Mori
Dec 19, 1995·Proceedings of the National Academy of Sciences of the United States of America·A MigliazzaR Dalla-Favera
Jun 1, 1996·The Journal of Pathology·S PittalugaC De Wolf-Peeters
May 1, 1996·Genes, Chromosomes & Cancer·G VolpeG Gaidano

❮ Previous
Next ❯

Citations

Jul 16, 2005·Hematology·Fabrice Jardin, Surinder S Sahota
May 16, 2000·Cancer Investigation·B H Ye
Jul 10, 2007·International Journal of Laboratory Hematology·A J BenchM A Scott
Jan 19, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Izidore S Lossos, Daniel Morgensztern
Sep 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pascale De PaepeChris De Wolf-Peeters
Jul 11, 2001·Advances in Anatomic Pathology·E D Hsi, S Yegappan
Dec 6, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·B E KingS H Swerdlow
Jun 24, 2009·Advances in Anatomic Pathology·Jonathan Said
May 8, 2003·European Journal of Nuclear Medicine and Molecular Imaging·A S Jack
Jan 8, 2000·International Reviews of Immunology·L M StaudtX Yu
May 17, 2005·Applied Immunohistochemistry & Molecular Morphology : AIMM·Yin XuSteven H Kroft
Dec 5, 2006·Journal of Clinical and Experimental Hematopathology : JCEH·Hitoshi Ohno
Mar 25, 1999·European Journal of Haematology·M JerkemanF Mitelman

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.